This is a preview of subscription content, log in via an institution to check access.
Notes
European Organization for the Research and Treatment of Cancer QoL Questionnaire C30
defined as a decline of 10 or 20 points on a given measure of the QLQ-C30 scale
References
Gourgou-Bourgade S, et al. Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial. Journal of Clinical Oncology : 3 Dec 2012. Available from: URL: http://dx.doi.org/10.1200/JCO.2012.44.4869
Ko AH, et al. Achieving the Best of Both Worlds. Journal of Clinical Oncology : 3 Dec 2012. Available from: URL: http://dx.doi.org/10.1200/JCO.2012.46.4891
Rights and permissions
About this article
Cite this article
FOLFIRINOX provides QOL benefits in pancreatic cancer. PharmacoEconomics & Outcomes News 669, 8 (2013). https://doi.org/10.1007/s40274-013-0060-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0060-z